Immunomodulatory enzyme company Hansa Biopharma on Friday announced the completion of enrollment of 15 patients under an investigator-initiated phase 2 study to evaluate the safety, tolerability and efficacy of imlifidase in severe Anti-GBM antibody disease .
Anti-GBM antibody disease, also known as Goodpasture's disease, is a severe kidney disease where the immune system mistakenly develops IgG-antibodies, resulting in an acute immune attack on the kidneys and in some patients also on the lungs. Severe Anti-GBM antibody disease may progress to renal failure or death. Anti-GBM antibody disease affects roughly one in a million annually.
According to the company, the first data read out from the anti-GBM study is expected in the third quarter of 2020.
The company added that the completion of enrollment in the anti-GBM study marks an important milestone for the expansion outside transplantation.
In 2018, the company received orphan drug designation for imlifidase for Anti-GBM antibody disease in both the EU and the US.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval